14 recruiting. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Recruiting 14 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety of Simplified Tranexamic Acid Regimen Tranexamic Acid (TXA) - Trauma Coagulopathy, Hemorrhage | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2026-10-01 | 2026-10-09 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| SWIFT - SWIss Factor XIII Trial in PPH Fibrogammin - Postpartum Hemorrhage, Coagulation Disorder | Phase 4 | Recruiting | Christian Haslinger | 988 | 2024-07-09 | 2026-04-27 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma Aspirin, Rivaroxaban - Multiple Myeloma, Venous Thromboembolism (VTE) | Phase 4 | Recruiting | Chen Lijuan | 200 | 2024-02-01 | 2026-10-30 |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) Elranatamab - Multiple Myeloma | Phase 4 | Recruiting | Pfizer | 80 | 2023-10-03 | 2026-07-01 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma Ixazomib plus low-dose lenalidomide, Ixazomib - Multiple Myeloma | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2022-07-01 | 2026-01-05 |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Cilta-cel - Multiple Myeloma | Phase 4 | Recruiting | Janssen Research & Development, LLC | 295 | 2022-03-09 | 2026-09-25 |
Multiple Myeloma (10) · Hemorrhage (2) · Neoplasms (2) · Cytokine Release Syndrome (1) · Glomerulonephritis (1) · Glomerulonephritis, IGA (1) · IgA Vasculitis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Neoplasms, Plasma Cell (1) · Peripheral Nervous System Diseases (1) · Postpartum Hemorrhage (1) · Recurrence (1) · Renal Insufficiency, Chronic (1)
Cardiovascular Diseases (14) · Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Hemorrhagic Disorders (14) · Vascular Diseases (14) · Immune System Diseases (12) · Blood Protein Disorders (11) · Immunoproliferative Disorders (11) · Lymphoproliferative Disorders (11) · Neoplasms by Histologic Type (11) · Paraproteinemias (11) · Neoplasms, Plasma Cell (10) · Neoplasms (9) · Pathologic Processes (6)
Dexamethasone (3) · Lenalidomide (3) · tocilizumab (2) · 4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 (S-S bridged) (1) · 4-fluorobenzoyl-TN-14003 (1) · Acetaminophen (1) · Angiotensin Receptor Antagonists (1) · Aspirin (1) · BKT140 (1) · Blood Component Removal (1) · Bortezomib (1) · Calcium Dobesilate (1) · Crossing Over, Genetic (1) · Everolimus (1) · Factor XIII (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · CHU de Quebec-Universite Laval (1) · Chen Lijuan (1) · Christian Haslinger (1) · Christian Medical College, Vellore, India (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Janssen Research & Development, LLC (1) · Pfizer (1) · Regeneron Pharmaceuticals (1) · Tanta University (1) · The First Affiliated Hospital of Soochow University (1) · University Health Network, Toronto (1)
China (6) · United States (5) · Canada (3) · Japan (2) · Spain (2) · Australia (1) · Belgium (1) · Egypt (1) · France (1) · India (1) · Israel (1) · Netherlands (1) · Switzerland (1) · Taiwan (1)
Ann Silk, MD (1) · Ashraf M Alaa, BSc of clinical pharmacy (1) · Beatrice Mosimann, Prof. Dr. (1) · Christian Haslinger, Prof. Dr. (1) · Christine Chen, Dr. (1) · Dr Vincent Laroche, MD,FRCPC (1) · George T John, DM, FRCP, FRACP (1) · Jarmila Zdanowicz, MD (1) · Jonathan Barratt, PhD, FRCP (1) · Joseph Rimando, MD (1) · Leila Sultan-Beyer, MD (1)
PMID 32176833, PMID 40345697, PMID 41472522
2023 (2), P30CA138292 (1)